astrazeneca glp 1 Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo AstraZeneca Pays $185M to Add

PMID 12355264

Schematic representation of the relationship between tyramine dose exposure and the severity of clinical responses, particularly in individuals with impaired tyramine metabolism such as those receiving monoamine oxidase inhibitor (MAOI) therapy

I havent had time to read it all completely but the conclusion was that they dont really know much about it

While Semaglutide and Tirzepatide have become household names, a growing number of patients are also exploring metabolic peptides such as AOD-9604, MOTS-c, and Tesamorelin

Data availability All data generated or analysed during this study are included in this published article and its supplementary information files